Pharmaceutical Industry Reports Pharmaceutical Industry Reports | Page 2

REPORT DESCRIPTION
Porphyria Treatment Market – Overview
Porphyria is an inherited rare disorder that affects the nervous system or skin and may cause abdominal pain. Cells
of porphyria patients are unable to change body chemicals called porphyrins and its precursors into heme, the
substance responsible for blood color. According to the National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK), the exact rates of porphyria are unknown and vary globally. For instance, porphyria cutanea
tarda is most common in the U.S., and variegate porphyria is frequent in South America. Some porphyrias such as
erythropoietic protoporphyria, hepatoerythropoietic porphyria, and congenital erythropoietic porphyria occur when
an individual receives two abnormal genes, one from each parent. The chances of an individual passing the
abnormal gene or genes to the next generation depends on the type of porphyria. Acute porphyrias affects the
nervous system and abdomen. Its attacks develop over hours or days and can last up to several weeks. Cutaneous
porphyrias affects the skin.
According to the American Porphyria Foundation, acute porphyria affects around 1 to 2 individual per 100,000.
High incidence rate was reported in South Africa and Sweden. The foundation promotes comprehensive care
necessary for treating individuals with Porphyria. It promotes the disease awareness, reduce the stigma associated
with porphyria through physician education, and provides support for those affected. The foundation also organized
the Porphyria Awareness Week in April 2018, 21-28.
© Coherent market Insights. All Rights Reserved